ALLO Feb 2025 1.500 call
| Previous close | 1.2500 |
| Open | N/A |
| Bid | 1.2000 |
| Ask | 1.5000 |
| Strike | 1.50 |
| Expiry date | 2025-02-21 |
| Day's range | 1.2500 - 1.2500 |
| Contract range | N/A |
| Volume | |
| Open interest | 1 |
Insider MonkeyAllogene Therapeutics, Inc. (ALLO): Among the Rising Penny Stocks to Invest In Now
We recently compiled a list of the 7 Best Rising Penny Stocks To Invest In Now. In this article, we are going to take a look at where Allogene Therapeutics, Inc. (NASDAQ:ALLO) stands against the other rising penny stocks. Fed’s Rate Cut Sets the Stage for a Strong Q4 In an episode of Market Storylines on […]
GlobeNewswireAllogene Therapeutics Announces Participation in the Goldman Sachs Cell Therapy Day Conference
SOUTH SAN FRANCISCO, Calif., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will participate in panel focused on innovations in the allogeneic cell therapy landscape during the Goldman Sachs Cell Therapy Day on October 1, 2024 in New York. Goldman Sachs Cell Therapy DayTuesday, October 1, 2024Panel D
- GlobeNewswire
Allogene Therapeutics to Present Pre-Clinical Data Highlighting the Potential of ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Diseases, at the American College of Rheumatology (ACR) Convergence
The CD19/CD70 Dual CAR is Specifically Designed to Address Both the B-cell and T-cell Dysfunction Implicated in Autoimmune DiseasesALLO-329, is an Investigational Product Built on a New Gene Editing Platform that Features Site-Specific Integration, Intended to Reduce the Risk of Secondary Malignancies, and Leverage the Clinically Validated Dagger® Effect Aimed at Reducing or Eliminating Lymphodepletion, a Potential Barrier in the Adoption of CAR T in Autoimmune Indications SOUTH SAN FRANCISCO, C
